Health news round-up: puberty blockers, oral GLP-1s and inequalities in neonatal care A weekly summary of important developments in pharmacy and health news that you may have missed.…
NICE recommends first licensed treatment for vitiligo Guidance says that ruxolitinib cream can be used as treatment for vitiligo if other first-line treatments — such as including topical corticosteroids and light therapy — do not work.…
Health news round-up: GLP-1s for psoriasis, promise for people with cancer and pharmacogenomics A weekly summary of important developments in pharmacy and health news that you may have missed.…
Everything you need to know about mpox Following the identification of a new strain in England — and an ongoing global outbreak of the most severe subgroup of mpox — here is a summary of the latest information and best practice for pharmacy professionals.…
Health news round-up: NICE approvals, surveillance data and GLP-1 warnings A weekly summary of important developments in pharmacy and health news that you may have missed.…
PJ view: Access to rare disease treatment should not be a rarity Policymakers and healthcare leaders must persevere with long overdue changes to improve access to treatments for rare diseases.…
Is a cure for epidermolysis bullosa on the horizon? New trials to repurpose drugs for the rare genetic skin condition epidermolysis bullosa are offering families a level of hope not seen before, raising the question of whether a cure may finally be in sight.…
Two-prescriber sign-off no longer required for isotretinoin The Medicines and Healthcare products Regulatory Agency said that scrapping the two-prescriber requirement will address delays in access to acne treatment for patients aged under 18 years old.…
Health news round-up: vaccinations off-site, child health and medicines shortages A weekly summary of important developments in health news that you may have missed.…
NICE approves twice-yearly infusion that ‘significantly outperforms’ usual treatments for severe lupus Guidance says obinutuzumab, taken with daily immunosuppressant tablet mycophenolate mofetil, could benefit around 12,000 people in England.…
